**Alternative Commercial Proposal Submission Form**

Note to respondents: information to support how to best develop an Alternative Commercial Proposal (ACP) is available in the ACP guidance document.

1. Contact details:

|  |  |
| --- | --- |
| Name of supplier |  |
| Contact person |  |
| Phone |  |
| Email address |  |

1. Proposal:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Item(s) from 2024/25 ITT: | | | | | | | | |
| Pharmaceutical (brand name) | Formulation | List price | Unit price | Pack Size | Lead time | Medsafe approval (Y/N) | Community/Hospital supply | |
|  |  |  |  |  |  |  |  | |
|  |  |  |  |  |  |  |  | |
| Other Pharmaceuticals | | | | | | | | |
| Pharmaceutical (brand name) | Formulation | List price | Unit price | Pack Size | Lead time | Medsafe approval (Y/N) | Community/Hospital supply | Schedule/ Options for Investment listing |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

1. Proposal summary (description of the proposal, including any proposed rebates and/or other special terms):
2. Confirmation that there are no intellectual property barriers (including patent barriers) to supply this product for the proposed indications in New Zealand, with additional information if required:
3. Description of any available implementation support:

|  |
| --- |
|  |